Updated:
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc., a publicly traded entity on the Nasdaq under the ticker CVKD, is dedicated to advancing tecarfarin, a vitamin K antagonist...
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc., a publicly traded entity on the Nasdaq under the ticker CVKD, is dedicated to advancing tecarfarin, a vitamin K antagonist designed to address the limitations of warfarin for patients with antiphospholipid syndrome (APS) and other thrombotic disorders. The company's pipeline is singularly concentrated on this drug candidate, which has received U.S. FDA Orphan Drug and Fast Track designations, reflecting a regulatory pathway built on unmet medical need rather than broad market size. The firm's strategy centers on clinical-stage development with a focus on regulatory approval and eventual commercialization of tecarfarin, targeting a niche patient population that lacks effective therapeutic options. Cadrenal engages in preclinical and clinical trials, and its operational footprint is primarily domestic, with a Delaware incorporation and a headquarters in Ponte Vedra, Florida, as disclosed in public filings. As of 2024, Cadrenal Therapeutics reported having approximately 2.9 million shares outstanding per SEC filings, with a market capitalization under $10 million, indicating a micro-cap stage with limited institutional ownership. The company has not disclosed a dedicated investment team beyond its executive leadership, which includes CEO Dr. Quang Pham, and has no additional offices or philanthropic structures publicly identifiable. Cadrenal's structural differentiator lies in its focused orphan drug approach — betting on a single asset in a regulatory framework that provides market exclusivity and development incentives. This narrow pipeline contrasts with broader biotech firms, making its valuation and risk profile tied entirely to tecarfarin's clinical and regulatory milestones. (based on public company disclosures and SEC filings, 2024)
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
What is Cadrenal Therapeutics' primary drug candidate?
Cadrenal's sole pipeline asset is tecarfarin, a modified vitamin K antagonist designed to be safer and more consistent than warfarin for patients with antiphospholipid syndrome and other thrombotic disorders. It is protected by Orphan Drug and Fast Track designations from the U.S. FDA (per SEC filings and public statements).
How is Cadrenal Therapeutics structured as an investment vehicle?
Cadrenal is a publicly traded corporation listed on the Nasdaq under ticker CVKD. It is not an asset manager or family office — it is a development-stage biopharmaceutical company that raises equity financing through public markets to fund clinical trials. Its value derives from future regulatory milestones and potential commercialization of tecarfarin.
What is the target patient population for tecarfarin?
Tecarfarin is primarily intended for patients with antiphospholipid syndrome (APS) who require anticoagulation but cannot tolerate or achieve stable dosing with warfarin. This represents a niche orphan market with an estimated annual incidence of 1-2 per 100,000 people in the U.S. (per FDA orphan drug designation documents).
Is Cadrenal Therapeutics rated by any analyst for investment?
As of mid-2024, Cadrenal Therapeutics had limited analyst coverage, typical for micro-cap biotech firms. The company's risks are concentrated on clinical success, regulatory approval, and financing — key factors for institutional due diligence. Publicly available valuation analyses are sparse, with most coverage from small-cap research platforms.
Does Cadrenal Therapeutics have any known institutional investors?
Public filings and 13G/13D reports, as of late 2024, show no large institutional holders with positions exceeding 5% of outstanding shares. The shareholder base consists primarily of retail investors, company management, and a small number of venture or angel investors from the company's early financing rounds. (per SEC EDGAR filings)
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: